Strategic medical executive with two decades of leadership in clinical development and medical affairs across rare diseases, oncology, and precision medicine. Experienced in directing Phase I–III programs, managing global teams, and overseeing regulatory strategy and KOL engagement. Proven success in therapeutic innovation, M&A support, and early-stage biotech scaling. Combines entrepreneurial insight with scientific rigor to accelerate novel therapies to market.